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Generation of HEK-293 stable cell lines with disrupted expression of 
ribosomal protein S6 kinase (S6K1) isoforms using the CRISPR/Cas9 
genome editing system
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Aim. To generate HEK-293 cells with disrupted expression of S6K1 isoforms: p85, p70 and 
p60. Methods. CRISPR/Cas9 gene editing, Western blotting, immunofluorescent analysis, 
RT-PCR analysis, MTT assay, scratch assay. Results. Several clones of HEK-293 cells with 
a complete loss of p85/p70/p60-S6K1 protein expression were generated. The effects of p85/
p70/p60-S6K1 knockout on Akt/mTORC1/S6K1 signaling and cell proliferation and migration 
were assessed. Conclusions. The generated cell lines can be used to study a role played by 
S6K1 in cell physiology and to gain more detailed insight into cellular functions of the S6K1 
isoforms. The HEK-293 cells exhibit downregulation of Akt phosphorylation on Ser473 and 
subsequent attenuation of cell growth rate, as well as inhibition of cell motility.
K e y w o r d s: mTOR/S6K1 signaling, CRISPR/Cas9, S6K1 isoforms. 
Introduction 
Ribosomal protein S6 kinase (S6K1) functions 
as a component of the mTOR/S6K-dependent 
signaling pathway that is a critical regulator 
of translation, cell growth, survival and pro-
liferation (reviewed in [1, 2]). S6K1 is an 
extensively studied serine/threonine kinase that 
exerts its effects downstream of mTORC1 
(mammalian target of rapamycin complex 1). 
The deregulation of the mTORC1/S6K1 sig-
naling axis has been linked to a number of 
disease states, including cancer progression, 
metabolic and neurological disorders and ag-
ing-related pathologies [3–5]. 
The human RPS6KB1 gene encoding S6 
kinase 1 resides within the 17q23 chromosome 
locus. Alternative splicing events or alternate 
translational start site utilization yield specific 
S6K1 protein isoforms. To date, the evidence 
suggests the existence of several S6K1 iso-
forms, including the well-studied 70 kDa S6K1 
and 85 kDa S6K1 (p70-S6K1 and p85-S6K1 
respectively), an oncogenic 31 kDa S6K1 
(p31-S6K1 or S6K1-isoform 2) and a 60 kDa 
S6K1 (p60-S6K1). The p70-S6K1 and p85-
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S6K1 isoforms differ only by the presence of 
an N-terminal 23 aa extension due to alterna-
tive ATG site usage (p85-S6K1 translates from 
the first ATG and p70-S6K1 from the second 
one) [6]. The origin of another S6K1 isoform, 
p60-S6K1, is not known, however, it is be-
lieved that it may represent a protein trans-
lated from an alternative translation start 
site [7], possibly a third ATG located 87 bp 
downstream of the second one. This is sup-
ported by PCR analysis data, as well as the 
data of Western Blot analysis which reveal that 
only antibodies specific to the C-terminal re-
gion of S6K1 (but not to the N-terminal re-
gion) can recognize p60-S6K1 [7]. 
Experiments using transgenic mice [8] indi-
cate that RPS6KB1 gene knockout significantly 
affects mice phenotype demonstrating a sig-
nificant decrease in body size, enhanced sensi-
tivity to insulin and, as a consequence, resis-
tance to high fat diet-induced obesity [8–10]. 
At the same time, RPS6KB1 knockout does not 
have a lethal effect on these mice, probably due 
to the existence of S6K2 that is highly homolo-
gous to S6K1 and shares most of substrates. 
Amplification of RPS6KB1 gene was found in 
tumors of different histotypes, including breast 
carcinoma where it was initially detected [11–
13]. The results obtained in [14, 15] demon-
strated that overexpression of S6K1 is accom-
panied by the kinase nuclear accumulation, and 
a correlation between S6K1 expression and 
tumor cell aggressiveness was observed [16, 
17]. In addition, there are some data indicating 
that resistance of estrogen positive tumors to 
anti-estrogen therapy is tightly linked to S6K1 
signaling [18, 19]. Despite numerous data sug-
gesting the oncogenic potential of S6K1, the 
contribution of each isoform is not clear yet. 
To evaluate the functional activity of dif-
ferent isoforms of S6K1 as well as their onco-
genic properties we planned to generate mod-
el cell lines with exclusive expression of spe-
cific S6K1 isoforms (p85, or p70, or p60). 
The main goal of present work was to produce 
the basic HEK-293 cells with a knockout of 
RPS6KB1 gene expression on protein level ap-
plying CRISPR/Cas9-mediated gene editing. The 
Clustered Regularly Interspaced Short Palind ro-
mic Repeats (CRISPR)/CRISPR-associated pro-
tein 9 nuclease (Cas9) is a prokaryotic adaptive 
immune system which has been used for genome 
engineering in recent years [20–22]. This genome 
editing system is based upon using a guide RNA 
(gRNA) sequence and the Cas9 endonuclease to 
introduce double-strand breaks in the targeted 
gene sequence that is complementary to gRNA. 
The genome double-strand breaks stimulate er-
ror-prone non-homologous end-joining (NHEJ) 
repair introducing mutagenic insertions or dele-
tions (InDels) at the DSB site, as well as high-
fidelity but less efficient Homology Directed 
Repair (HDR). 
Once RPS6KB1 knockout in HEK-293 has 
been confirmed by PCR, Western blot and im-
munofluorescence analysis, we analyzed how it 
affected phosphorylation status of the major 
S6K1 substrates, cell proliferation and their 
migratory potential. These cells will be further 
used for generation of HEK-293 cells exhibiting 
particular expression of different S6K1 isoforms. 
Materials and Methods 
gRNA design and cloning. gRNA oligonucle-
otides complementary to the sequence of the 
target gene were designed using the web tool 
http://crispr.mit.edu/. The sequences of gRNA 
oligonucleotides are the following: top strand – 
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CACCGACTTCGGGTACTTGGTAAAG, bot-
tom strand – AAACCTTTACCAAGTACCCG 
AAGTC, where the sequences underlined with 
a solid line correspond to the sequence of the 
S6K1 gene and the sequences without lines 
correspond to the Esp3I restriction site se-
quence. To clone the gRNA oligonucleotides in 
pSpCas9(BB)-2A-Puro (PX459) V2.0 vector 
(Addgene) they were annealed and ligated with 
the vector treated with the Esp3I restriction 
enzyme. For a ligation reaction T4 DNA ligase 
(ThermoScientific) was used. After ligation the 
construct was cloned in E.coli strain XL-GOLD. 
The presence of the insert was verified using 
PCR amplification and sequencing. For PCR 
amplification a primer corresponding to the U6 
promoter was used as a forward primer (GAG 
GGCCTATTTCCCAT GATTCC) and the bot-
tom gRNA oligonucleotide (AAACCTTTACC 
AAGTACCCGAAGTC) as a reverse primer. 
Sequencing of the insert was performed by us-
ing Applied Biosystems™ 3130 DNA Analyzer. 
Cell culture and generation of HEK-293 
cells with the edited S6K1 gene. Human em-
bryonic kidney cells (HEK-293) were main-
tained in DMEM medium containing 10 % 
heat-inactivated fetal bovine serum (FBS) 
(GIBCO), 100 units/ml penicillin, and 100 μg/
ml streptomycin. Transfection of S6K1 spe-
cific gRNAs into HEK-293 cells was carried 
out using jetPEI transfection reagent (Polyplus-
transfection ® SA). The procedure was per-
formed following manufacturer’s instructions. 
The cells were seeded onto a 24-well plate 
before transfection. The cells were grown for 
24 hours following transfection with 1 μg of 
DNA (pSpCas9(BB)-2A-Puro (PX459) V2.0/
S6K1). The cells were seeded onto 10-sm cell 
culture dishes 24 hours posttransfection and 
selected with puromycin (4 μg/mL) for 48 
hours. After selection the clones were picked 
up. The cells were cultured in an incubator 
with 5 % CO2 at 37C. 
Western blot analysis. Cells were washed 
with ice-cold PBS and lysed on ice for 30 min 
in 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 
1 mM EDTA, 1 mM EGTA, 0.5 % Triton 
X-100, supplemented with a Complete EDTA-
free protease inhibitor cocktail tablet (Roche). 
Whole-cell lysates were centrifuged at 12,000 
g for 15 min at +4 °C, and the supernatant was 
collected. The protein concentrations were 
determined using Bradford assay. Equal 
amounts of protein were resolved on 10 % 
SDS-PAGE and electrotransferred onto poly-
vinylidene difluoride (PVDF) membranes for 
immunoblotting. The antibodies were diluted 
for use as follows: anti-S6K1-C-terminus (gen-
erated as described in [23]) 1:2500, anti-β-
actin (clone 13E5, Sigma) 1:20000, anti-pho-
pho-S6 ribosomal protein (Ser235/236) (#2211, 
Cell Signaling Technologies) 1:2000, anti-
phospho-S6 ribosomal protein (Ser240/244) 
(#5364, Cell Signaling Technologies) 1:2000, 
anti-phospo-eIF4B (Ser422) (#3591, Cell 
Signaling Technologies) 1:2000, anti-phospho-
eEF-2K (Ser366) (#3691, Cell Signaling Tech-
no logies) 1:2000, anti-phospho-Akt (Ser473) 
(#9271, Cell Signaling Technologies) 1:2000. 
PCR analysis of cDNA from HEK293 
clones. The efficiency of CRISPR/Cas9 in 
HEK-293 was checked by RT-PCR. Total 
mRNA was isolated from cells using GeneJET 
RNA purification kit (ThermoScientific). 
cDNA was synthesized with RevertAid using 
oligo(dT)18 according to manufacturer’s rec-
ommendations (ThermoScientific). RT-PCR 
analysis was done with DreamTaq DNA poly-
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merase (ThermoScientific). The following 
primers were used for PCR amplification: for 
the 5’-end of the S6K1 transcript sequence – 
Forward (F1) – CTTCCGAGACAGGGAAG 
CTG, Reverse (R1) – GCCAAGTAAAAGC 
AGGCAGTG; for the 3’-end of S6K1 – For-
ward (F2) – CACCTCGAAGATTTATTGGCA, 
Reverse (R2) – GTGCTCTGGCCGTTTGG. 
Immunofluorescent analysis of HEK-293 
clones. HEK-293 cells (clones 5 and 6) were 
seeded onto cover glasses and cultured several 
days. After reaching 70–80 % of confluent mono-
layer, cells were fixed with 10 % neutral buffered 
formalin. Thereafter, the cells were permeabi-
lized by 15 min incubation in 100μl PBS with 
0.2 % Triton X-100. Non-specific binding was 
blocked by incubation with 10 % FCS in PBS 
for 30 min at 37 °C. For S6K1 detection samples 
were incubated with rabbit polyclonal anti-C-
terminal S6K1 antibo di es [23] in dilution 1:100 
in PBS overnight at +4 °C. The secondary FITC 
conjugated anti-rabbit antibody was applied in 
dilution 1:400 (Jackson ImmunoResearch) in 
100μl PBS. The samples were embedded into 
Mowiol (Sigma) medium containing 2,5 % 
DABCO (Sigma) and 0,5 mg/ml DAPI (Pierce). 
All microscopy studies were performed using 
Zeiss LSM 510 META microscope (Germany). 
MTT assay. The p85–/p70–/p60– HEK-293 and 
wtHEK-293 cells were seeded in 96-well plates 
at a density of 5000 cells in 100 µl per well and 
grown for 24, 48 and 72 hours. At the end of 
incubation, 20 µl of 5 mg/ml MTT (3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide) were added to each well and incubated for 
3 h. Following incubation with MTT, 150 µl of 
DMSO was added to dissolve formazan crystals 
and absorbance was measured at 570 nm. 
Experiments were performed in triplicate. 
Scratch assay. p85–/p70–/p60– HEK-293 and 
wtHEK-293 were plated onto a 35-mm dish and 
grown until 100% confluence to form a mono-
layer. A scratch was created with a pipette tip 
across the diameter of the dish. The cells were 
washed once with PBS and then replaced with 
fresh medium. At time points of 0 and 24 h of 
incubation, the cells were examined using Leica 
DM 1000 microscope, the images were acquired 
and further analysed quantitatively by ImageJ 
that measured the distance (µm) travelled during 
the 24 h time frame. Each experiment was re-
peated three times. 
Statistical analysis. All results are expressed 
as the mean ± standard deviation (S.D.) from 
three independent experiments. Statistical sig-
nificance between two groups was determined 
by using Student’s t-test. The difference be-
tween groups was considered to be statisti-
cally significant at p < 0.01 and p < 0.005. 
Results and Discussion
S6K1 gene gives rise to a number of S6K1 iso-
forms through usage of alternate ATG start sites 
(p85-S6K1 and p70-S6K1) or via translation of 
alternatively spliced mRNA (p31-S6K1 or 
S6K1-isoform 2) (reviewed in [1, 2]). According 
to existing data, translation of the S6K1 proteins 
may be initiated from two start codons all being 
present in the S6K1 transcript variant encoding 
the p85-protein causing expression of p85-S6K1 
and p70-S6K1, respectively. The origin of an-
other S6K1 isoform (p60-S6K1) missing a part 
of an N-terminal region is not known, however, 
one cannot exclude that it may represent a pro-
tein translated from the alternative translation 
start site [7] that represents a functionally active 
S6K1 isoform. We believe that p60 is translated 
from the third ATG located 87 bp downstream 
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of the second ATG that is a translation start for 
the p70-S6K1 isoform (Fig. 1). 
In this work we aimed to generate HEK-293 
cell lines with disrupted expression of S6K1 
isoforms, including p85, p70 and p60, applying 
CRISPR/Cas9-mediated gene editing. Taking 
into account the prediction that p60-S6K1 
isoform could be translated from the alterna-
tive translation start site, we designed gRNA 
(20 nt) targeting 279-298 bp region down-
stream of the third ATG (Fig. 1). 
The reason for why the HEK-293 cells be-
came a choice in this work is that they can be 
easily and promptly reproduced and main-
tained, as well as they allow high efficiency of 
transfection [24]. In addition, they are well-
studied in context of S6K1-dependent signal-
ing. HEK-293 cell line is considered to be 
hypotriploid. Nevertheless, their modal chro-
mosome number may differ depending upon 
the source of the HEK-293 cells [25, 26]. Thus 
any individual HEK-293 cell can bear a dif-
ferent number of RPS6KB1 gene copies, and 
in case CRISPR/Cas9 approach is applied, 
each copy can be mutated by the CRISPR/
Cas9 system in a distinct way within a cell. 
To generate S6K1 knockout, we transfected 
the HEK-293 cells with pSpCas9(BB)-2A-Puro 
(PX459) V2.0 encoding anti-p85/p70/p60-S6K1 
gRNA with following 48 h selection. Upon selec-
tion, six clones were picked up and checked for 
S6K1 lesions by Western blot technique using 
antibodies specific to the C-terminal (aa 453-525) 
region of S6K1 [23]. Wild type HEK-293 cells 
(wtHEK-293) were used as control cells.  
S6K1 specific antibodies revealed targeting 
of all the S6K1 isoforms by anti-p85/p70/p60 
gRNA. The S6K1 knockout in HEK-293 cells 
was confirmed in three out of six clones (#4 – 
6) by Western blot analysis (Fig. 2). In one 
clone (#3), we observed a significant down-
regulation of all S6K1 isoforms. That may 
represent the case when at least one allele left 
intact. In addition, one of the generated clones 
(#1) expressed a novel S6K1-related polypep-
tide that is longer than p70-S6K1, and other 
two clones (#1, #2) expressed a polypeptide 
with electrophoretic mobility similar to that of 
p60-S6K1. Expression of the S6K1-related 
peptides may occur due to to a randomness of 
mutations caused by NHEJ action after a 
CRISPR/Cas9-mediated DNA cleavage. 
Fig. 1. The schematic representation of S6K1 domain organization and gRNA design for S6K1 gene editing using 
CRISPR/Cas9 genome editing technology. The figure shows the S6K1 transcript encoding the p85-, p70- and p60-
S6K1 isoforms with three corresponding alternative start sites (including the hypothetical third start for p60-S6K1) 
designated as bent right arrows. A black colored region depicts the gRNA targeted region (279-298 nucleotides). F1 
and R1 are primers used for PCR analysis of the targeted 5’-region in the S6K1 transcript; F2 and R2 are primers used 
for PCR analysis of the intact 3’-region of the S6K1 transcript. 
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Taking into account that our goal was to 
generate HEK-293 cells that would not express 
any of known S6K1 isoforms, we selected the 
clones (#5 and #6) where expression of S6K1 
was not detected at all by anti-S6K1 anti bo di es 
specific to the kinase C-terminus for further 
analysis. 
The following immnofluorescent analysis 
of selected clones with the same anti-S6K1 
antibodies specific to the kinase C-terminal 
region have confirmed a complete loss of S6K1 
expression (Fig. 3). In addition, alterations in 
selected clones #5 and #6 were confirmed by 
RT-PCR analysis using oligonucleotides spe-
cific to the downstream and upstream region 
of the targeted sequence (Fig. 4). PCR analysis 
of S6K1 mRNA expression using oligonucle-
otides specific to the untargeted 3’-sequence 
did not reveal any alterations suggesting that 
Fig. 2. Analysis of S6K1 isoforms expression in clones 
of HEK293 cells after S6K1 gene editing. Western-blot 
analysis of HEK293 cell lysates with antibodies specific 
to the C-terminal region of S6K1. β-actin was used as a 
loading control. 1 – MCF-7wt; 2 – HEK293wt; 3-8 – 
HEK293 clones (1 - 6) with gRNA targeted S6K1 gene. 
Fig. 3. Immunofluorescent detection 
of S6K1 with antibodies specific to 
the C-terminal region of S6K1 in pa-
rental HEK-293 cells and in HEK293 
clones (5 and 6) after CRISPR/Cas9 
induced S6K1 gene editing.
362
I. V. Zaiets, A. S. Sivchenko, A. I. Khoruzhenko et al.
CRISPR/Cas9 genome editing did not affected 
S6K1 expression on a transcriptional level. 
We also observed Cas9 nuclease expression 
in all the individual CRISPR/Cas9 clones (data 
not shown). Therefore, the S6K1 knockout 
cells (clone #5, #6) could be used in studies 
involving only transient (but not stable) S6K1 
isoforms expression. 
After we generated the S6K1 knockout HEK-
293 cells, our next goal was to estimate an impact 
of S6K1 gene disruption on phosphorylation of 
the major S6K1 substrates and some cellular 
processes controlled by intact S6K1, including 
cell proliferation and migration. We first exam-
ined the phosphorylation pattern of the S6K1-
regulated proteins. We did not observe any dif-
ferences in the phosphorylation status of ribo-
somal protein S6 (rpS6) on both Ser235/236 and 
Ser240/244 between wtHEK-293 and p85–/p70–/
p60– HEK-293 (Fig. 5). Indeed, apart from S6K1 
there are several other AGC kinases that target 
rpS6, including RSK (phosphorylates rpS6 on 
Ser235/236) and S6K2 (promotes phosphoryla-
tion of rpS6 on Ser235/236/240/244). Studies 
using both cultured mammalian cells with RNAi-
mediated S6K1 knockdown and S6K1 knockout 
mice report a decrease in rpS6 phosphorylation 
on each of four sites mentioned above [27, 28]. 
In our cells treated with CRISPR/Cas9, however, 
RSK and S6K2 appear to completely compensate 
for S6K1-mediated rpS6 phosphorylation. Such 
a discrepancy could be explained by using differ-
ent cell types and/or various methods of S6K1 
silencing. Except for rpS6, several other proteins 
implicated in translation regulation also represent 
well-known S6K1 substrates, including eIF4B 
and eEF-2K. Additionally, these S6K1-regulated 
substrates are also controlled by RSK-mediated 
phosphorylation. Our data shows that S6K1 
knockout HEK-293 display a lower level of eI-
Fig. 4. PCR analysis of cDNA isolated from generated HEK-293 clones after 
CRISPR/Cas9 induced editing of the S6K1 gene. A top panel represents PCR 
analysis of cDNA selected clones with primers specific to 5’-end of S6K1 
transcripts (F1, R1) where targeted sequence is located. The resulted PCR 
product contains a mutated sequence. The other panels show PCR products 
with primers specific to 3’-end of S6K1 (F2, R2) and β-actin. 1 – negative 
control; 2 – clone 5; 3 – clone 6; 4 – wtHEK-293.
Fig. 5. Effect of S6K1 gene disruption on Akt/mTOR/S6K1 signaling in 
HEK293 cells. After 24 hours of serum starvation, HEK-293 cells with S6K1 
gene knockout were treated with 20 % fetal bovine serum (FBS) for 1 hour. 
Protein lysates were prepared from the cells and analyzed for the Akt/mTOR/
S6K1 signalling pathway by Western blotting. Antibody against β-actin was 
used to ensure each protein sample was loaded equally. 
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F4B phosphorylation on Ser422 compared to 
HEK-293, but the levels of phospho-eEF-2K 
(Ser366) remain unchanged (Fig. 5). Consistently, 
a similar pattern of eIF4B phosphorylation was 
observed after S6K1 knockdown [27]. 
Surprisingly, Akt Ser473 phosphorylation 
significantly decreased in response to S6K1 
knockout in comparison with wtHEK-293 
(Fig. 5). In contrast to our results, evidence 
exists for an increase of Akt Ser473 phos-
phorylation in S6K1 knockdown rhabdomyo-
sarcoma cell lines [29]. Meanwhile, recent data 
obtained suggest either unchanged phospho-
Akt Ser473 levels or even a drop in Ser473 
phosphorylation when authors applied methods 
of chemical or genetic inhibition of S6K1, re-
spectively in [30]. Additionally, MEFs derived 
from S6K1–/– S6K2–/– mice displayed normal 
levels of Akt Ser473 phosphorylation [31]. 
A number of studies demonstrated the ability 
of S6K1 to regulate actin cytoskeleton and a cell 
migration rate [32, 33]. In comparing wtHEK-293 
with p85–/p70–/p60– HEK-293, we observed a 
decrease in migration rate of the p85–/p70–/p60– 
HEK-293 cells (Fig. 6), further supporting the idea 
that S6K1 at least in part controls cell motility. 
Since S6K1 promotes anabolic processes, 
including protein and lipid synthesis [1], with-
in the mTORC1 signaling network in a cell, an 
ability of a cell to grow and proliferate is also 
dependent on S6K1. In our study, we applied 
MTT assay to estimate a rate of p85–/p70–/p60– 
HEK-293 cell proliferation. Apparently, the 
p85–/p70–/p60– HEK-293 cells grew at a lower 
rate than control wtHEK-293 (Fig. 7). Our re-
sults underscore the role for S6K1 in regulation 
of cell growth and proliferation in agreement 
with the data reported by other authors [34]. 
We assume that reduced cell proliferation 
and migration rates of p85–/p70–/p60– HEK-
(1) (2) (1) (2)
Fig. 6. Analysis of p85–/p70–/p60– 
HEK-293 migration by in vitro 
scratch assay. The confluent p85–/
p70–/p60– HEK-293 (2) cells were 
subjected to in vitro scratch assay 
with images captured at 0 and 24 h 
after incubation. *, p < 0.01, versus 
wtHEK-293 (1). Experiments were 
repeated in triplicate.
Fig. 7. CRISPR/Cas9-mediated knockout of S6K1 inhib-
its HEK-293 cell proliferation. p85–/p70–/p60– HEK-293 
and wtHEK-293 were seeded in 96-well plates and cul-
tured for 24, 48 and 72 hours. At the end of the incuba-
tion, MTT was added and absorbance measured. The data 
are presented as the mean ± S.D. *p < 0.005. 
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293 could be caused by decreased Akt Ser473 
phosphorylation. Akt is one of the cell cycle 
regulators; it can also be critical for migratory 
properties of a cell (reviewed in [35]). Even 
though S6K1 represents a well-known negative 
regulator of Akt via a negative feedback loop 
downregulating gene expression of IRS1/2 [36, 
37], several other less-studied mTOR-depen-
dent feedbacks can negatively modulate Akt 
function [38, 39]. Possibly, some of these feed-
back loops become hyper-activated under the 
condition of CRISPR-mediated S6K1 knock-
out in the HEK-293 cells. Further studies are 
required to define the mechanism underlying 
Akt regulation by S6K1 in the HEK-293 cells. 
In conclusion, we generated mutant HEK-293 
cells with a complete loss of p85/p70/p60-S6K1 
protein expression by CRISPR/Cas9 gene editing. 
The generated cells can be used for creation of 
cell models with ectopic expression of different 
S6K1 isoforms enabling to gain more detailed 
insight into S6K1 isoforms cellular function. 
These cells also provide an opportunity to inves-
tigate crosstalk or compensatory mechanisms 
existing between different cell signaling pathways 
which regulate fundamental cellular processes.
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Створення стабільних ліній клітин HEK-293 
з порушеною експресією ізоформ кінази 
рибосомного білка S6 (S6K1) за допомогою 
системи редагування генома CRISPR/Cas9
І. В. Заєць, А. С. Сівченко, А. І. Хоруженко, 
В. В. Філоненко 
Мета. Створити клітини HEK293 з порушеною екс-
пресією S6K1 ізоформ: p85, p70 і Р60. Методи. 
CRISPR/cas9 система редагування генома, Вестерн-
блот, імунофлуоресцентний аналіз, ПЛР-аналіз, MTT 
тест, метод «раневої поверхні». Результати. Отримано 
декілька клонів клітин НЕК-293 з повною втратою 
експресії білка p85/p70/p60-S6K1. Було оцінено ефект 
нокауту p85/p70/p60-S6K1 на Akt/mTORC1/S6K1 сиг-
налінг та клітинні проліферацію і міграцію. Висновки. 
Створені клітинні лінії можуть бути використані для 
вивчення ролі, яку відіграє S6K1 в фізіології клітини, 
що дозволяє отримати більш детальне уявлення про 
клітинні функції ізоформ S6K1. Клітини p85–/p70–/
p60– HEK-293 виявляють знижений рівень фосфори-
лювання Akt по Сер473 і подальше пригнічення швид-
кості клітинного росту разом з інгібуванням клітинної 
рухливості. 
К л юч о в і  с л о в а: mTOR/S6K1 сигналювання, 
CRISPR/Cas9, ізоформи S6K1. 
Создание стабильных линий клеток HEK-293 
с нарушенной экспрессией изоформ киназы 
рибосомного белка S6 (S6K1) при помощи 
системы редактирования генома CRISPR/Cas9 
И. В. Заец, А. С. Сивченко, А. И. Хоруженко, 
В. В. Филоненко 
Цель. Создать клетки HEK293 с нарушенной экспрес-
сией S6K1 изоформ: p85, p70 и Р60. Методы. CRISPR/
cas9 система редактирования генома, Вестерн-блот, 
иммунофлуоресцентный анализ, ПЦР-анализ, MTT 
тест, метод «раневой поверхности». Результаты. 
Получено несколько клонов клеток НЕК-293 с полной 
потерей экспрессии белка p85/p70/p60-S6K1. Была 
проведена оценка влияния нокаута p85/p70/p60-S6K1 
на Akt/mTORC1/S6K1 сигналинг и клеточные проли-
ферацию и миграцию. Выводы. Созданные клеточные 
линии могут быть использованы для изучения роли, 
которую играет S6K1 в физиологии клетки и позволить 
получить более детальное представление о клеточных 
функциях изоформ S6K1. Клетки p85–/p70–/p60– HEK-
293 показывают пониженный уровень фосфорилиро-
вания Akt по Сер473 и дальнейшее угнетение скорости 
клеточного роста вместе с ингибированием клеточной 
подвижности. 
К л юч е в ы е  с л о в а: mTOR/S6K1 сигналинг, 
CRISPR/Cas9, изоформы S6K1.
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